#India #Bengaluru #Biocon #CEO #Shreehas Tambe

Shreehas Tambe Appointed CEO and Managing Director of Biocon Limited

Biocon Limited, a leading global biopharmaceutical company, has announced the appointment of Shreehas Tambe as Chief Executive Officer (CEO) and Managing Director, effective April 1, 2026. This pivotal appointment, pending approval from the Board of Directors and the Nomination and Remuneration Committee, marks a significant step in the company’s evolution.

As the first executive to hold the position of CEO, Tambe will guide Biocon’s integrated platform that spans biosimilars and generics, reinforcing the organization’s capacity to compete effectively on the global stage. Alongside this, Kedar Upadhye has been named Chief Financial Officer, indicating a shift in the leadership structure aimed at enhancing operational efficiency and strategic alignment.

This management transition follows the complete integration of Biocon Biologics Limited, positioning Biocon as a unified entity to take on pressing global health challenges. The reorganized structure will enable the company to excel in critical health areas such as diabetes, oncology, and immunology by leveraging a differentiated portfolio that includes biosimilars, complex generics, and innovative peptides, notably GLP-1 therapies.

Kiran Mazumdar-Shaw, Executive Chairperson of Biocon Limited, expressed confidence in Tambe’s leadership, citing his instrumental role in driving several strategic initiatives, including the acquisition of Viatris’ biosimilars business. Under Tambe’s stewardship, Biocon Biologics has emerged as one of the top global players in the biosimilars sector, with an estimated valuation of $5.5 billion, showcasing the company's potential in transforming healthcare access dynamics.

“Biocon has always been at the forefront of anticipating patient needs and evolving with industry changes,” Mazumdar-Shaw noted. She reiterated her belief in Tambe’s ability to execute a disciplined approach to leadership while nurturing a sustainable global standing.

Reflecting on his appointment, Tambe remarked, “Leading Biocon at this crucial juncture is both an honor and a privilege. Our mission remains to harness the power of science and technology to ensure vital treatment access. By expanding our portfolio and global presence, I will focus on enhancing our foundations and promoting sustainable growth.”

Shreehas Tambe has almost three decades of experience with Biocon, having joined as a management trainee and rising through the ranks in various leadership roles. His previous tenure as CEO and Managing Director of Biocon Biologics Limited helped propel the company to become a top contender in the biosimilars market, underpinned by his commitment to innovation and strategic growth.

In his new capacity, Tambe aims to solidify Biocon's status as a leading biopharmaceutical enterprise, adept at addressing critical health needs globally through a robust range of biosimilars, insulin products, generics, and peptides. His academic credentials include a master’s degree in Bioprocess Technology from the University of Mumbai, along with multiple industry awards that affirm his influence and leadership in the biopharmaceutical space.

Biocon Limited, headquartered in Bengaluru, India, is committed to making transformative medicines accessible and tackling global health challenges, especially chronic diseases. The company has launched 12 biosimilars and over 30 generics globally, showcasing its diverse product pipeline and commitment to serving unmet medical needs.

With a presence in over 120 countries and a strong workforce exceeding 9,500 employees, Biocon embodies a proactive stance on health equity and sustainability. As the company prepares to embark on this new chapter under Tambe’s leadership, it reinforces its pledge to innovate and expand access to health care solutions worldwide.